Picture

Anmol Singh, MD @MDanmolsingh

Heme/Onc at @VCSpecialists passionate about taking care of patients with breast cancer. Trained by @DukeIMResidency & @MDAndersonNews. Views my own. she/her Arlington, VA Joined June 2019
  • Tweets
    693
  • Followers
    718
  • Following
    566
  • Likes
    5K
Anmol Singh, MD retweeted
medoncodoc Profile Picture

Goutham Sunny @medoncodoc

2 months ago

A nice review on Postmastectomy RT and RNI in the era of de-escalation of treatment #bcsm doi.org/10.1200/OP-25-… @ErikaHamilton9 @DrAGraff @stolaney1 @hoperugo @matteolambe @jamecancerdoc @drsarahsam @JankovicK @antgiorda @DrHBurstein @nlinmd @BianchiniGP @Dr_RShatsky…

Anmol Singh, MD retweeted
DrHBurstein Profile Picture

Harold J. Burstein, MD, PhD, FASCO @DrHBurstein

3 months ago

Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. @ASCO #ASCO25 @OncoAlert

Anmol Singh, MD retweeted
NEJM Profile Picture

NEJM @NEJM

3 months ago

Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:…

Anmol Singh, MD retweeted
to_be_elizabeth Profile Picture

Elisabetta Bonzano MD, PhD @to_be_elizabeth

3 months ago

📌 Do We "Node" What to Do About the Axilla❓ Great discussion👏🏻 ✨Mediget Teshome, MD, FACS, MPH @OncoAlert #OncoAlertAF #ASCO25

Anmol Singh, MD retweeted
DrSGraff Profile Picture

Stephanie Graff, MD, FACP, FASCO @DrSGraff

3 months ago

SOFT/TEXT 15 year update #ASCO25 2/2

Anmol Singh, MD retweeted
drsarahsam Profile Picture

Dr Sarah Sammons @drsarahsam

3 months ago

Dr Sonya Reid makes excellent point in Metastatic TNBC Sadly 50% of patients do not make it to second line therapy in mTNBC. In that case, waiting beyond first line to give a more effective regimen seems silly. #bcsm #ASCO25

Anmol Singh, MD retweeted
lungoncdoc Profile Picture

Eric K. Singhi, MD @lungoncdoc

3 months ago

Slide updated! ✔️ Looking forward to the presentation here at #ASCO25 @ASCO

NEJM Profile Picture

NEJM @NEJM

3 months ago

Slide updated! ✔️ Looking forward to the presentation here at #ASCO25 @ASCO https://t.co/h4RI1kPodR

Anmol Singh, MD retweeted
to_be_elizabeth Profile Picture

Elisabetta Bonzano MD, PhD @to_be_elizabeth

3 months ago

📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer. ✨Erica L. Mayer, MD, MPH, FASCO ✔️Rapid Oral Abstract Session Breast Cancer-Local/Regional/ Adjuvant @OncoAlert #OncoAlertAF #ASCO25 #Day3

Anmol Singh, MD retweeted
ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

Dr. Frank Sinicrope presents ATOMIC, chemo +/- atezolizumab as adjuvant tx for Stage III dMMR colon cancer. 54% of patients high risk (T4/N2). 3-year DFS 86.4 vs 76.6%, HR 0.50 (P<0.0001) @ALLIANCE_org #ASCO25

Anmol Singh, MD retweeted
ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

Atezo arm with doubling of G4 neuropathy (14 vs 7%) and more patient deaths. Do these patients need oxaliplatin? #ASCO25

ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

Atezo arm with doubling of G4 neuropathy (14 vs 7%) and more patient deaths. Do these patients need oxaliplatin? #ASCO25 https://t.co/gUk314bBtI

Anmol Singh, MD retweeted
ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

Dr. Chalabi proposes that lower risk tumors get treated with surgery, chemo/IO per ATOMIC and higher risk tumors consider neoadjuvant IO per NICHE-2. #ASCO25

ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

Dr. Chalabi proposes that lower risk tumors get treated with surgery, chemo/IO per ATOMIC and higher risk tumors consider neoadjuvant IO per NICHE-2. #ASCO25

Anmol Singh, MD retweeted
ASCO Profile Picture

ASCO @ASCO

3 months ago

1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?

Anmol Singh, MD retweeted
ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

Key Takeaways from Dr. DeMichele #ASCO25

Anmol Singh, MD retweeted
DrSGraff Profile Picture

Stephanie Graff, MD, FACP, FASCO @DrSGraff

3 months ago

.@NRGonc BR003 shows adding carboplatin to weekly paclitaxel following DD AC for adj tx of node-positive or high-risk node-negative TNBC did NOT result in a statistically significant improvement in IDFS #ASCO25 @OncoAlert

Anmol Singh, MD retweeted
ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

This is what I’ll take away from #ASCO25. And two additional points: 1. It received a standing ovation 2. Did not have to say overall survival data hadn’t matured … in contrast to the plenary session’s abstracts. It should have been included!

ryanhuey Profile Picture

Ryan Huey, MD, MS @ryanhuey

3 months ago

This is what I’ll take away from #ASCO25. And two additional points: 1. It received a standing ovation 2. Did not have to say overall survival data hadn’t matured … in contrast to the plenary session’s abstracts. It should have been included!

Anmol Singh, MD retweeted
PTarantinoMD Profile Picture

Paolo Tarantino @PTarantinoMD

3 months ago

Tremendous discussion of the SERENA-6 trial by @AngieDemichele. Outstanding results, though not ready for clinical practice (yet). Important to take into account financial, psychological & systemic costs of the strategy. Make sure to review this presentation if you missed it.

Anmol Singh, MD retweeted
DrSGraff Profile Picture

Stephanie Graff, MD, FACP, FASCO @DrSGraff

3 months ago

A practice changing trial that IMMEDIATELY needs to be challenged. 2L TDXd only 10%, adj SOC was less than usual, and given PATINA 44mos, a stop-TDXd switch to CDK4/5 + H(P) needs to be explored for QOL. We should not minimize the 48% Fatigue, incld ~8% G3 #ASCO25 @OncoAlert

Anmol Singh, MD retweeted
Dr_ElvinaA Profile Picture

Elvina Almuradova @Dr_ElvinaA

3 months ago

Very important Insight at #ASCO25 >10% of ER -/low breast cancer patients had increased ER expression in residual tumors post-NAC ✅Retesting can unlock adjuvant endocrine therapy. ⬇️Don’t skip it if there’s residual disease! meetings.asco.org/abstracts-pres… #Oncology @OncoAlert @ASCO

Anmol Singh, MD retweeted
Dr_RShatsky Profile Picture

Rebecca Shatsky, MD @Dr_RShatsky

3 months ago

Toxicity with this regimen is high. And I don’t mean hyperglycemia. I mean stomatitis. It works well if you can stay on it, but that’s a big if. #ASCO25 #bcsm

PTarantinoMD Profile Picture

Paolo Tarantino @PTarantinoMD

3 months ago

Toxicity with this regimen is high. And I don’t mean hyperglycemia. I mean stomatitis. It works well if you can stay on it, but that’s a big if. #ASCO25 #bcsm

Anmol Singh, MD retweeted
nlinmd Profile Picture

Nancy Lin, MD @nlinmd

3 months ago

More evidence for the value of cdk4/6 inhibitor in 1L patients with triple positive (ER+/HER2+) breast cancer. -ORR 61% with a non chemo containing regimen -mPFS 30 months

Trends for United States

Iowa
22,5 B posts
#UFCParis
16,7 B posts
Karen
203 B posts
San Jose State
3.126 posts
Baylor
5.926 posts
Penn State
6.350 posts
Duke
22,2 B posts
Drew Allar
SJSU
1.791 posts
Davey Johnson
6.877 posts
Livingstone
2.451 posts
Sam Patterson
Elizabeth Warren
48,6 B posts
CJ Bailey
Andrel Anthony
Kevin Jennings
Sperry
Hardwick
1.676 posts
Gronowski
1.001 posts
Cashius Howell

You might like

GI Medical Oncologist at MD Anderson Cancer Center. Opinions my own. Follow me on Instagram @gi.onc.doc
Madhu Eluri, MD
@MadhuEluri
1K Followers
Thoracic medical oncologist @MDAndersonNews, former hospitalist/clinical informaticist @UCLA, love classical music and nature.
Bingnan Zhang
@BZhangMD
582 Followers
Thoracic Medical Oncologist, Assistant Professor @MDAndersonNews | Patient education & young-onset lung cancer | 🫁#cancer #lcsm @LungCancerRx | Views my own
Eric K. Singhi, MD
@lungoncdoc
6K Followers
Duke Transplant Hepatology/Gastroenterology @Duke_GI_ co-APD for Duke IM Resident recruitment @IMResidencyDuke #ALD and #MedEd. Go blue! | Views my own
Steph Garbarino MD
@GarbarinoSteph
416 Followers
Med onc and health systems researcher at UAB; I study legal systems, health law, and policy; Johns Hopkins Oncology & Duke Medicine alum.
Qasim Hussaini, MD
@QasimHussainiMD
1K Followers
Hematologist/Medical Oncologist | Interest in hematological malignancies | Tweets/opinions are mine ≠ medical advice #CART #Lymphoma #lymsm
Owhofasa Agbedia, MD,...
@FasaAgbedia
881 Followers
Breast oncologist @DFCI, proud mama, coffee enthusiast, trail runner, and world class parallel parker
Claire E.P. Smith
@ClaireSmithMD
225 Followers
Interventional Cardiologist and Endovascular Specialist @VUMCDiscoveries. Passionate about vascular care. Views are my own, L/RT≠endorsement.
Alex Sullivan
@AlexSullivan_MD
642 Followers
Assistant prof @SylvesterCancer focused on gastric & esophageal cancer | Trained @MDAndersonNews @IMResidencyDuke & @UFMedicine | Wife & Mom | Go gators! 🐊
Cindy M. Pabon, MD
@cmpabon
946 Followers